Netherlands-based molecular diagnostic company SkylineDx has entered a strategic partnership with German lab developer NeraCare to co-develop a proteomic test called “Immunoprint” for survival prediction of melanoma patients.
Immunoprint by NeraCare will help life science companies bring melanoma therapies to market faster by identifying high-risk, early-stage melanoma patients. Both companies will work exclusively together to develop and license Immunoprint while leveraging SkylineDx's global network and discovery expertise, and will present validation data at the 2023 European Association of Dermato-Oncology congress.
SkylineDx is a biotech company specializing in molecular diagnostics for oncology and inflammatory diseases. SkylineDx's lead product is MMprofiler with SKY92, a clinical test that measures the activity of 92 cancer genes and is used to aid physicians in the prognosis of multiple myeloma. The company also has a R&D program called “Falcon” that aims to develop an array of diagnostic utilities for melanoma patients, providing physicians with the tools to optimize the clinical pathway of their patients.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.